Why Is ROIVANT SCIENCES LTD (ROIV) Stock Up Today?

ROIV stock surged 19.00% to $41.57 on Tuesday, driven by positive Phase 2 trial results for its experimental drug mosliciguat. The trial, known as PHocus, demonstrated a 56.3% reduction in pulmonary vascular resistance compared to placebo after 16 weeks. Jefferies also raised its price target for the stock to $52 from $42, adding to the momentum.

What Happened

Roivant Sciences announced the successful outcome of the PHocus trial for mosliciguat, which targets pulmonary hypertension associated with interstitial lung disease. The results were presented at the European Respiratory Society International Congress on September 8, 2026. The company filed an 8-K with the SEC, disclosing the data under Regulation FD. The stock opened with a 23.4% gap up from the previous close, reaching $43.10, and traded as high as $43.93 before settling at $41.51. The positive data and analyst upgrade from Jefferies fueled the session’s sharp rise.

What The Data Shows

The stock has traded 1.2 times its 3-month average volume, with 7.2 million shares exchanged so far. Over the past 8 sessions, ROIV had fallen 6.0% from $36.56 to $34.37. On Tuesday, it broke its 52-week high of $37.97, printing a fresh 52-week high. Insider selling has been heavy in the past 90 days, with 11 transactions totaling $247.5 million. However, the recent trial results and analyst upgrade have shifted the focus to the drug’s potential.

What To Watch

The stock is now trading near its all-time high. Investors should monitor the broader market reaction to the PHocus data and any follow-up guidance from Roivant. Coverage breadth is expanding, with 15 stories from 11 sources in the last 36 hours.